Q-omics provides the consensus-scored MAGEA9B profile across patient tissues and cancer cell-line models. MAGEA9B expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, MAGEA9B is differentially expressed in 5, with the highest sampling consensus in HNSC. Additionally, MAGEA9B RNA expression shows 6,594 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight STAD, HNSC, and TGCT as cancer lineages where MAGEA9B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAGEA9B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAGEA9B survival associations across molecular data types. MAGEA9B RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAGEA9B RNA expression–survival associations across cancer types. High MAGEA9B expression shows unfavorable associations in STAD, COAD, MESO, CESC, BRCA and UVM. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify STAD as the clearest survival context for MAGEA9B RNA expression.
This table summarizes MAGEA9B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for MAGEA9B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAGEA9B shows lower tumor expression in KIRC and higher tumor expression in HNSC, LUSC, BLCA and LUAD. The HNSC box plot shows higher MAGEA9B RNA expression in tumor versus normal tissue (log2 FC = +0.521, t-test p < 0.001).
This table shows molecular features associated with MAGEA9B in patient tissues and cancer cell lines. In patient samples, MAGEA9B shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAGEA9B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LUNG_SCLC.
